Corporate Partners

Vitrolife 
The Vitrolife Group is a global leader in reproductive health focused on supporting customers and patients worldwide to improve treatment. Based on science and advanced research capabilities, Vitrolife aims to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality.
In 2023, Memphasys signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife Group, to sell and distribute the FelixTM System for sperm separation in Japan for five years. This has now been extended to Canada and New Zealand.

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

For investor and media enquiries:
David Tasker, Chapter One Advisors
E: dtasker@chapteroneadvisors.com.au
M: +61 433 112 936

Find

Level 1, 34-36 Richmond Road,
Homebush West, NSW 2140
Australia

Call

Privacy Preference Center